1. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study). Issue 7 (28th January 2014) Authors: Meiners, P M; Vissink, A; Kroese, F G M; Spijkervet, F K L; Smitt-Kamminga, N Sillevis; Abdulahad, W H; Bulthuis-Kuiper, J; Brouwer, E; Arends, S; Bootsma, H Journal: Annals of the rheumatic diseases Issue: Volume 73:Issue 7(2014) Page Start: 1393 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Issue 2 (12th August 2013) Authors: Moerman, R V; Arends, S; Meiners, P M; Brouwer, E; Spijkervet, F K L; Kroese, F G M; Vissink, A; Bootsma, H Journal: Annals of the rheumatic diseases Issue: Volume 73:Issue 2(2014) Page Start: 472 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjögren's syndrome. Issue 12 (17th July 2013) Authors: Pollard, R P E; Abdulahad, W H; Bootsma, H; Meiners, P M; Spijkervet, F K L; Huitema, M G; Burgerhof, J G M; Vissink, A; Kroese, F G M Journal: Annals of the rheumatic diseases Issue: Volume 72:Issue 12(2013) Page Start: 2048 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. Issue 8 (17th January 2012) Authors: Meiners, P M; Arends, S; Brouwer, E; Spijkervet, F K L; Vissink, A; Bootsma, H Journal: Annals of the rheumatic diseases Issue: Volume 71:Issue 8(2012) Page Start: 1297 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗